[Translation] A multicenter, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of Binapuxi granules in the treatment of common cold (febrile cold)
以服药3天全部症状消失率为主要疗效指标,与安慰剂对照,在Ⅱ期临床试验基础上,进一步评价比那甫西颗粒治疗普通感冒(热性感冒)的有效性与安全性,最终为药物注册申请获得批准提供充分依据。
[Translation] Taking the rate of disappearance of all symptoms after taking the medicine for 3 days as the main efficacy indicator and comparing with placebo, on the basis of Phase II clinical trials, the effectiveness and safety of Binapuxi Granules in treating the common cold (febrile cold) were further evaluated, ultimately providing sufficient basis for the approval of the drug registration application.